Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RVMD Stock Forecast 2026-2027
$179.18
Current Price
$39.32B
Market Cap
Buy 22
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RVMD Price Targets
+46.8%
To High Target of $263.00
+12.7%
To Median Target of $201.98
-15.7%
To Low Target of $151.00
RVMD Price Momentum
-4.1%
1 Week Change
+13.6%
1 Month Change
+358.8%
1 Year Change
+125.0%
Year-to-Date Change
-7.6%
From 52W High of $193.83
+427.0%
From 52W Low of $34.00
📊 TOP ANALYST CALLS
Did RVMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if REVOLUTION Medicines is one of their latest high-conviction picks.
Latest RVMD Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, RVMD has a bullish consensus with a median price target of $201.98 (ranging from $151.00 to $263.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $179.18, the median forecast implies a 12.7% upside. This outlook is supported by 22 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RVMD Analyst Ratings
22
Buy
1
Hold
0
Sell
RVMD Price Target Range
Low
$151.00
Average
$201.98
High
$263.00
Current: $179.18
Latest RVMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RVMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 9, 2026 | Guggenheim | Michael Schmidt | Buy | Maintains | $235.00 |
| Jul 6, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $195.00 |
| Jul 6, 2026 | Mizuho | Joseph Catanzaro | Outperform | Maintains | $215.00 |
| Jul 2, 2026 | Wedbush | Robert Driscoll | Outperform | Maintains | $181.00 |
| Jun 30, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Jun 29, 2026 | Needham | Buy | Maintains | $N/A | |
| Jun 10, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Jun 2, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 1, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| May 22, 2026 | Bernstein | Market Perform | Initiates | $N/A | |
| May 18, 2026 | Truist Securities | Gregory Renza | Buy | Assumes | $179.00 |
| May 7, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 7, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| May 7, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| May 7, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 7, 2026 | Needham | Buy | Maintains | $N/A | |
| Apr 22, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Apr 22, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 20, 2026 | Stifel | Buy | Reiterates | $N/A |
Revolution Medicines Inc. (RVMD) Competitors
The following stocks are similar to REVOLUTION Medicines based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RVMD
Revolution Medicines
mkt cap
39.73B
Revolution Medicines Inc. (RVMD) Financial Data
Revolution Medicines Inc. has a market capitalization of $39.32B with a P/E ratio of -30.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -76.7%.
Valuation Metrics
Market Cap
$39.32B
Enterprise Value
$37.64B
P/E Ratio
-30.5x
PEG Ratio
-0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+5.0%
Current Ratio
6.8x
Debt/Equity
29.2x
ROE
-76.7%
ROA
-37.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Revolution Medicines Inc. (RVMD) Business Model
About Revolution Medicines Inc.
What They Do
Develops targeted therapies for cancer treatment.
Business Model
The company operates as a clinical-stage precision oncology firm, focusing on developing therapies that target specific molecular alterations in cancer cells. It generates revenue through collaborations with healthcare providers and research institutions, advancing its drug pipeline which includes innovative inhibitors aimed at critical signaling pathways in tumors.
Additional Information
Founded in 2004 and based in Redwood City, California, the company emphasizes research into hard-to-target cancer mechanisms, particularly the RAS and mTOR pathways. Its investigational therapies are being explored both as standalone treatments and in combination with other therapies to enhance efficacy against various cancers.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
883
CEO
Dr. Mark A. Goldsmith M.D., Ph.D.
Country
United States
IPO Year
2020
Website
www.revmed.comRevolution Medicines Inc. (RVMD) Latest News & Analysis
Latest News
Quick Summary
Axsome has a strong late-stage pipeline and expanding commercial drug offerings. Revolution's recent phase 3 trial indicates potential advancements in cancer treatment.
Why It Matters
Axsome's strong pipeline and successful drugs indicate potential revenue growth, while Revolution's promising trial results suggest breakthroughs in cancer treatment, impacting future valuations and market potential.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
The European Medicines Agency has initiated a rolling review of Revolution Medicines' experimental treatment for metastatic pancreatic cancer.
Why It Matters
The rolling review by the European Medicines Agency could accelerate approval for Revolution Medicines' treatment, potentially boosting its market value and attracting investor interest.
Source: Reuters
Market Sentiment:
Neutral
Quick Summary
Revolution Medicines is advancing its lead cancer treatment toward regulatory review, indicating potential upcoming developments in its therapeutic offerings.
Why It Matters
Revolution Medicines' innovative cancer treatment nearing regulatory review could lead to significant market opportunities, impacting stock performance and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Revolution Medicines' daraxonrasib is undergoing a phased review by the EMA for pancreatic cancer, recognized as an orphan drug and prioritized under the Cancer Medicines Pathfinder project.
Why It Matters
The phased review by the EMA for daraxonrasib suggests a faster path to market, potentially boosting Revolution Medicines' stock and attracting investor interest due to its high unmet medical need status.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Several biotech companies have reached key milestones, with recent drug approvals potentially boosting the performance of one company significantly.
Why It Matters
Recent drug approvals indicate potential growth and profitability for biotech companies, impacting stock prices and investor sentiment, particularly for the standout performer.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Revolution Medicines (Nasdaq: RVMD) has reported results from Phase 1/2 trials of zoldonrasib, a RAS G12D inhibitor, for treating metastatic pancreatic cancer.
Why It Matters
Positive clinical trial results for zoldonrasib could enhance Revolution Medicines' market position and attract investment, signaling potential growth in the oncology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RVMD Stock
What is Revolution Medicines Inc.'s (RVMD) stock forecast for 2027?
Based on our analysis of 9 Wall Street analysts, Revolution Medicines Inc. (RVMD) has a median price target of $201.98. The highest price target is $263.00 and the lowest is $151.00.
Is RVMD stock a good investment in 2027?
According to current analyst ratings, RVMD has 22 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $179.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RVMD stock?
Wall Street analysts predict RVMD stock could reach $201.98 in the next 12 months. This represents a 12.7% increase from the current price of $179.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Revolution Medicines Inc.'s business model?
The company operates as a clinical-stage precision oncology firm, focusing on developing therapies that target specific molecular alterations in cancer cells. It generates revenue through collaborations with healthcare providers and research institutions, advancing its drug pipeline which includes innovative inhibitors aimed at critical signaling pathways in tumors.
What is the highest forecasted price for RVMD Revolution Medicines Inc.?
The highest price target for RVMD is $263.00 from at , which represents a 46.8% increase from the current price of $179.18.
What is the lowest forecasted price for RVMD Revolution Medicines Inc.?
The lowest price target for RVMD is $151.00 from at , which represents a -15.7% decrease from the current price of $179.18.
What is the overall RVMD consensus from analysts for Revolution Medicines Inc.?
The overall analyst consensus for RVMD is bullish. Out of 9 Wall Street analysts, 22 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $201.98.
How accurate are RVMD stock price projections?
Stock price projections, including those for Revolution Medicines Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:12 AM UTC